Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)

Part of paid clinical trials in Portland, Oregon.

Sponsor
Oregon Health and Science University
Study ID
NCT03485976
Phase
PHASE2
Status
Completed

Conditions

  • Pityriasis Rubra Pilaris

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Ixekizumab — DRUG
    Treatment at the FDA-approved psoriasis dosing

Study Details

15 patients with PRP will be treated with ixekizumab for 24 weeks to determine safety and efficacy. Participants are required to travel to Portland, OR only for the first visit and week-24 visit. 5 visits in between these times and one follow up visit may be performed by secure videoconferencing.

Key Dates

Start date
May 23, 2018
Status verified
Jun 2020
Primary completion
Oct 14, 2019
Completion
Jan 13, 2020

Study Design

Enrollment
12 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ixekizumab treatment arm
    Ixekizumab 160 mg subcutaneous injection at week 0, followed by 80 mg subcutaneous injections at week 2, 4, 6, 8, 10, 12, 16, and 20

Primary Outcome Measure

Clinical Improvement in PRP Severity and Body Surface Area [ Time Frame: 24 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Oregon Health and Science UniversityPortlandOregon97239-

Find similar trials in Portland, OR

By research site
Oregon Health and Science University· Portland, OR

Related Studies